Merck & Company, Inc. (MRK)
Latest news, insights and market data
Market Data
AI Insights
Merck's KEYTRUDA has received European Commission approval for use in combination with Padcev for treating muscle-invasive bladder cancer. This expands the application of KEYTRUDA, enhancing its position in oncology and potentially driving future revenues. The approval reflects ongoing advancements in Merck's cancer treatment portfolio.
Latest News
| Title | Published |
|---|---|
How Unusual Is Zoetis's Latest Sales Growth? How Unusual Is Zoetis's Latest Sales Growth? | about 7 hours ago |
How Unusual Is Zoetis's Latest Sales Growth? For questions about this article or underlying research, email [email protected]. | about 7 hours ago |
Are You Overpaying For Regeneron Stock Versus Its Rivals? Are You Overpaying For Regeneron Stock Versus Its Rivals? | about 13 hours ago |
Are You Overpaying For Regeneron Stock Versus Its Rivals? For questions about this article or underlying research, email [email protected]. | about 13 hours ago |
Merck (MRK) Laps the Stock Market: Here's Why Merck (MRK) Laps the Stock Market: Here's Why | about 14 hours ago |
Merck (MRK) Laps the Stock Market: Here's Why The latest trading day saw Merck (MRK) settling at $149.88, representing a +1.07% change from its previous close. | about 14 hours ago |
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock? Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock? | about 14 hours ago |
How Unusual Is Zoetis's Latest Sales Growth?
How Unusual Is Zoetis's Latest Sales Growth?
How Unusual Is Zoetis's Latest Sales Growth?
For questions about this article or underlying research, email [email protected].
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Are You Overpaying For Regeneron Stock Versus Its Rivals?
For questions about this article or underlying research, email [email protected].
Merck (MRK) Laps the Stock Market: Here's Why
Merck (MRK) Laps the Stock Market: Here's Why
Merck (MRK) Laps the Stock Market: Here's Why
The latest trading day saw Merck (MRK) settling at $149.88, representing a +1.07% change from its previous close.
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?